Supernus Pharmaceuticals, Inc.
General ticker "SUPN" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $2.1B (TTM average)
Supernus Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 50.3%.
Estimated limits based on current volatility of 1.0%: low 44.24$, high 45.35$
Factors to consider:
- Total employees count: 674 (+3.4%) as of 2024
- Top business risk factors: Regulatory and compliance, Market competition, Reimbursement risks, Distributor dependency, Succession planning
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [29.54$, 43.67$]
- 2025-12-31 to 2026-12-31 estimated range: [29.64$, 44.27$]
Financial Metrics affecting the SUPN estimates:
- Positive: with PPE of 14.8 at the end of fiscal year the price was neutral
- Positive: 7.86 < Operating profit margin, % of 12.34
- Negative: negative Industry operating cash flow (median)
- Positive: 6.82 < Operating cash flow per share per price, % of 8.66
- Positive: Shareholder equity ratio, % of 75.71 > 63.39
- Positive: Industry inventory ratio change (median), % of -1.41 <= -0.15
- Positive: -14.38 < Investing cash flow per share per price, % of -9.56
- Positive: Inventory ratio change, % of -3.72 <= -0.75
Short-term SUPN quotes
Long-term SUPN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $667.24MM | $607.52MM | $661.82MM |
| Operating Expenses | $621.11MM | $612.79MM | $580.15MM |
| Operating Income | $46.12MM | $-5.27MM | $81.67MM |
| Non-Operating Income | $14.62MM | $8.04MM | $16.20MM |
| Interest Expense | $7.07MM | $2.42MM | $0.00MM |
| R&D Expense | $74.55MM | $91.59MM | $108.80MM |
| Income(Loss) | $60.74MM | $2.77MM | $97.87MM |
| Taxes | $0.03MM | $1.45MM | $24.00MM |
| Profit(Loss)* | $60.71MM | $1.32MM | $73.86MM |
| Stockholders Equity | $886.20MM | $921.52MM | $1,035.73MM |
| Inventory | $91.54MM | $77.41MM | $54.29MM |
| Assets | $1,702.51MM | $1,277.67MM | $1,368.07MM |
| Operating Cash Flow | $116.83MM | $111.08MM | $171.95MM |
| Capital expenditure | $0.41MM | $0.55MM | $0.72MM |
| Investing Cash Flow | $-216.66MM | $268.73MM | $-189.87MM |
| Financing Cash Flow | $-10.48MM | $-397.88MM | $12.19MM |
| Earnings Per Share** | $1.13 | $0.02 | $1.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.